Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes

被引：0
作者：
Lesley J. Scott
机构：
[1] Springer,
来源：
Drugs | 2017年 / 77卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Subcutaneous insulin glargine/lixisenatide (Suliqua™) is a titratable, fixed-ratio combination of a long-acting basal insulin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of adult patients with inadequately controlled type 2 diabetes. Once-daily insulin glargine/lixisenatide, in combination with metformin, provided effective glycaemic control and was generally well tolerated in the 30-week, multinational, phase 3 LixiLan-O and LixiLan-L trials in insulin-naive and -experienced adult patients with inadequately controlled type 2 diabetes. Although long-term clinical experience with this fixed-ratio combination is currently lacking, given its convenient once-daily regimen and beneficial effects on glycaemic control and bodyweight loss in the absence of an increase in the incidence of hypoglycaemia, insulin glargine/lixisenatide is an emerging option for the treatment of adult patients with type 2 diabetes to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another OAD or basal insulin.
引用
收藏
页码：1353 / 1362
页数：9
相关论文
共 74 条
[1]  
Inzucchi SE(2012)Diagnosis and classification of diabetes mellitus Diabetes Care 35 S64-S71
[2]  
Bergenstal RM(2015)Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149
[3]  
Buse JB(2016)Combination therapy for improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: rationale and evidence for early initiation J Diabetes Complicat 30 1177-1185
[4]  
Milligan S(2016)Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in type 2 diabetes, with special reference to IDegLira Diabet Med 33 864-876
[5]  
Wilding JPH(2016)Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Diabet Obes Metabol 18 203-216
[6]  
Bain SC(2016)Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness Ther Adv Chronic Dis 7 4-17
[7]  
Nauck M(2014)Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis The Lancet 384 2228-2234
[8]  
Anderson SL(2016)Insulin glargine 300 U/mL: a review in diabetes mellitus Drugs 76 363-374
[9]  
Trujillo JM(2003)Insulin glargine: an updated review of its use in the management of diabetes mellitus Drugs 63 1743-1778
[10]  
Eng C(2013)Lixisenatide: a review of its use in patients with type 2 diabetes mellitus BioDrugs 27 509-523
12345678